808 related articles for article (PubMed ID: 12707709)
21. [Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
Bailbé M; Karolewicz S; Neau JP; Dumas P; Gil R;
Rev Neurol (Paris); 2002 Feb; 158(2):203-10. PubMed ID: 11965176
[TBL] [Abstract][Full Text] [Related]
22. [Parkinson disease. Directed use of modern therapy].
Möller JC; Wächter T; Oertel WH
MMW Fortschr Med; 2001 May; 143 Suppl 2():45-50. PubMed ID: 11434257
[TBL] [Abstract][Full Text] [Related]
23. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.
Paus S; Brecht HM; Köster J; Seeger G; Klockgether T; Wüllner U
Mov Disord; 2003 Jun; 18(6):659-67. PubMed ID: 12784269
[TBL] [Abstract][Full Text] [Related]
24. [Therapy of Parkinson disease. 1: Standard therapy of motor and non-motor symptoms].
Kuhn W; Müller T
Fortschr Neurol Psychiatr; 1997 Aug; 65(8):361-74. PubMed ID: 9378449
[TBL] [Abstract][Full Text] [Related]
25. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
26. Treatment options for early Parkinson's disease.
Stacy M; Brownlee HJ
Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572
[TBL] [Abstract][Full Text] [Related]
27. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
Cools R
Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
[TBL] [Abstract][Full Text] [Related]
28. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
Mercuri NB; Bernardi G
Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
[TBL] [Abstract][Full Text] [Related]
29. [Controversial issues concerning the initial treatment of Parkinson's disease: L-Dopa or dopaminergic agonists?].
Defer GL
Rev Neurol (Paris); 1999 Jan; 155(1):43-5. PubMed ID: 10093847
[No Abstract] [Full Text] [Related]
30. Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment.
Wolters EC
Neurology; 1999; 52(7 Suppl 3):S10-3. PubMed ID: 10227604
[TBL] [Abstract][Full Text] [Related]
31. [Current preclinical findings on substances against Parkinson's disease].
Gerlach M; Riederer P
Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
[TBL] [Abstract][Full Text] [Related]
32. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients.
Goetz CG; Wuu J; Curgian L; Leurgans S
Mov Disord; 2006 Feb; 21(2):267-70. PubMed ID: 16161144
[TBL] [Abstract][Full Text] [Related]
33. [Advances in the medical treatment of Parkinson's disease].
Chaná P
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S22-5. PubMed ID: 20082996
[TBL] [Abstract][Full Text] [Related]
34. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
Greene P; Cote L; Fahn S
Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
[No Abstract] [Full Text] [Related]
35. Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease.
Nissen T; Newman EJ; Grosset KA; Daghem M; Pal G; Stewart M; Odin P; Macphee GJ; Grosset DG
Scott Med J; 2012 Nov; 57(4):217-20. PubMed ID: 23002158
[TBL] [Abstract][Full Text] [Related]
36. Parkinson's disease: diagnosis and treatment.
Rao SS; Hofmann LA; Shakil A
Am Fam Physician; 2006 Dec; 74(12):2046-54. PubMed ID: 17186710
[TBL] [Abstract][Full Text] [Related]
37. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
38. The two faces of L-DOPA: benefits and adverse side effects in the treatment of Encephalitis lethargica, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis.
Foster HD; Hoffer A
Med Hypotheses; 2004; 62(2):177-81. PubMed ID: 14962622
[TBL] [Abstract][Full Text] [Related]
39. Effective strategies in the management of Parkinson's disease.
Wills AJ
Hosp Med; 1998 Apr; 59(4):287-90. PubMed ID: 9722367
[TBL] [Abstract][Full Text] [Related]
40. An approach to the continuous dopaminergic stimulation in Parkinson's disease.
Schwartz M; Sabetay S
Isr Med Assoc J; 2012 Mar; 14(3):175-9. PubMed ID: 22675859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
